Treats hypertension. ANDA 208783, held by Novast Labs. Diltiazem Hydrochloride.
As of Nov 16, 2026, ANDA 208783 (Diltiazem Hydrochloride), held by Novast Labs, was first approved by FDA on Jun 14, 2019, with 2 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Diltiazem hydrochloride extended-release capsules are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Diltiazem hydrochloride extended-release capsules are indicated for the management of chronic stable angina and angina due to coronary artery spasm.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 14, 2019 | Original application | Approved | None posted |
| Diltiazem Hydrochloride120MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride180MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride240MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride300MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Diltiazem Hydrochloride360MG · capsule, extended release;oral | Diltiazem Hydrochloride | Rx |
| Jul 14, 2026 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jan 16, 2025 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 14, 2019 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters